May-Lucie Meyer, Medical Oncologist at Lausanne University Hospital, shared a post on LinkedIn:
“One week before our next workshop, I’m pleased to share this publication reporting the latest ETOP IBCSG reflections on TCEs, bringing together a multidisciplinary, cross-disease perspective on this rapidly evolving and promising class of drugs, highlighting both their potential and the key questions that remain for their optimal use in clinical practice.
Looking forward to continuing the discussion at the upcoming workshop!”
Title: T-cell engagers in small-cell lung cancer: current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation Workshop
Authors:
Read the full article.
You can also read: REZILIENT3 Trial: Major Positive Phase 3 Result in Exon 20 NSCLC